Marfan Sartan: A randomized, double-blind, placebo-controlled trial

European Heart Journal

Volumn 36, Issue 32, 2015, Pages 2160-2166

  Milleron, Olivier ^a   Arnoult, Florence ^a   Ropers, Jacques ^b   Aegerter, Philippe ^b,c   Detaint, Delphine ^a   Delorme, Gabriel ^a   Attias, David ^a   Tubach, Florence ^a,d,e   Dupuis Girod, Sophie ^f   Plauchu, Henry ^f   Barthelet, Martine ^g   Sassolas, Francois ^g   Pangaud, Nicolas ^g   Naudion, Sophie ^h   Thomas Chabaneix, Julie ^h   Dulac, Yves ⁱ   Edouard, Thomas ⁱ   Wolf, Jean Eric ^j   Faivre, Laurence ^j   Odent, Sylvie ^k   Basquin, Adeline ^l   Habib, Gilbert ^m   Collignon, Patrick ^m   Boileau, Catherine ^a,e,n   Jondeau, Guillaume ^a,n   more..

^a BICHAT HOSPITAL   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HÔTEL DIEU   (France)

^g South Lyon Hospital   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j DIJON UNIVERSITY HOSPITAL   (France)

^k UNIVERSITÉ DE RENNES 1   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

ⁿ Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

more..

Author keywords

Aorta; Echocardiography; Marfan; Sartan

Indexed keywords

ATENOLOL; LOSARTAN; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AORTA SINUS; AORTA SURGERY; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; HYPOTENSION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; SUDDEN DEATH; SUICIDE; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; ADOLESCENT; AGED; AORTIC DISEASES; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DILATATION, PATHOLOGIC; DRUG ADMINISTRATION; DRUG EFFECTS; HEART RATE; HYPERTENSION; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTIC DISEASES; BLOOD PRESSURE; DILATATION, PATHOLOGIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MARFAN SYNDROME; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84940197893     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv151     Document Type: Article

References (35)

1. Nienaber CA, Akin I, Eggebrecht H, Erbel R, Haverich A. Diseases of the aorta and trauma to the aorta and the heart. In John Camm TFL A, SerruysPatrick W, eds. The ESC Textbook of Cardiovascular Medicine. Oxford: Oxford University Press 2009 p1173-1214.
2. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-2957.
3. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiographyand Interventions, Societyof Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010;121:e266-e369.
4. Jondeau G, Detaint D, Tubach F, Arnoult F, Milleron O, Raoux F, Delorme G, Mimoun L, Krapf L, Hamroun D, Beroud C, Roy C, Vahanian A, Boileau C. Aortic event rate in the Marfan population: a cohort study. Circulation 2012;125:226-232.
5. Detaint D, Faivre L, Collod-Beroud G, Child AH, Loeys BL, Binquet C, Gautier E, Arbustini E, Mayer K, Arslan-Kirchner M, Stheneur C, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Plauchu H, Robinson PN, Kiotsekoglou A, De Backer J, Ades L, Francke U, De Paepe A, Boileau C, Jondeau G. Cardiovascular manifestations in men and women carrying a FBN1 mutation. Eur Heart J 2010;31:2223-2229.
6. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006;312:117-121.
7. Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med 2014;371:2061-2071.
8. Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, Faivre LO, Delrue MA, Collignon P, Odent S, Tchitchinadze M, Bouffard C, Arnoult F, Gautier M, Boileau C, Jondeau G. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapyversusplacebo in individuals with Marfan syndrome. Arch Cardiovasc Dis 2010;103:317-325.
9. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996;62:417-426.
10. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr [Practice Guideline]. 2005;18:1440-1463.
11. Stheneur C, Collod-Beroud G, Faivre L, Buyck JF, Gouya L, Le Parc JM, Moura B, Muti C, Grandchamp B, Sultan G, Claustres M, Aegerter P, Chevallier B, Jondeau G, Boileau C. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet 2009;17:1121-1128.
12. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol [Comparative Study]. 1989;64:507-512.
13. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994;330:1335-1341.
14. Team RC. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing 2012.
15. Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC III. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008;358:2787-2795.
16. Chiu HH, Wu MH, Wang JK, Lu CW, Chiu SN, Chen CA, Lin MT, Hu FC. Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 2013;88:271-276.
17. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ. Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol 2005;96:1441-1444.
18. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010;47:476-485.
19. Faivre L, Collod-Beroud G, Ades L, Arbustini E, Child A, Callewaert BL, Loeys B, Binquet C, Gautier E, Mayer K, Arslan-Kirchner M, Grasso M, Beroud C, Hamroun D, Bonithon-Kopp C, Plauchu H, Robinson PN, De Backer J, Coucke P, Francke U, Bouchot O, Wolf JE, Stheneur C, Hanna N, Detaint D, De Paepe A, Boileau C, Jondeau G. The new Ghent criteria for Marfan syndrome: what do they change? Clin Genet 2012;81:433-442.
20. Yang JH, Han H, Jang SY, Moon JR, Sung K, Chung TY, Lee HJ, Ki CS, Kim DK. A comparison of the Ghent and revised Ghent nosologies for the diagnosis of Marfan syndrome in an adult Korean population. Am J Med Genet A 2012;158A:989-995.
21. Bowen JM, Connolly HM. Of Marfan's syndrome, mice, and medications. N Engl J Med 2014;371:2127-2128.
22. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-1401.
23. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation 2012;126:2976-2982.
24. McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H, Black A, Kearney S, Kay E, Hill AD, Dietz HC, Redmond JM. Pravastatin reduces Marfan aortic dilation. Circulation 2011;124(11 Suppl.):S168-S173.
25. Yang HH, Kim JM, Chum E, van Breemen C, Chung AW. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J Thorac Cardiovasc Surg 2010;140:305-312 e2.
26. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011;332:361-365.
27. Nichols WW, Denardo SJ, Wilkinson IB, McEniery CM, Cockcroft J, O'Rourke MF. Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform. J Clin Hypertens (Greenwich) 2008;10:295-303.
28. Jondeau G, Boutouyrie P, Lacolley P, Laloux B, Dubourg O, Bourdarias JP, Laurent S. Central pulse pressure is a major determinant of ascending aorta dilation in Marfan syndrome. Circulation 1999;99:2677-2681.
29. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2013;75:79-92.
30. Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. Am J Cardiol 1998;82:203-208.
31. Segers P, De Backer J, Devos D, Rabben SI, Gillebert TC, Van Bortel LM, De Sutter J, De Paepe A, Verdonck PR. Aortic reflection coefficients and their association with global indexes of wave reflection in healthy controls and patients with Marfan's syndrome. Am J Physiol Heart Circ Physiol 2006;290:H2385-H2392.
32. Yang HH, Kim JM, Chum E, van Breemen C, Chung AW. Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome. Br J Pharmacol 2009;158:1503-1512.
33. Duranteau J, Pussard E, Berdeaux A, Giudicelli JF. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers. Br J Clin Pharmacol 1995;40:431-438.
34. Ladouceur M, Fermanian C, Lupoglazoff JM, Edouard T, Dulac Y, Acar P, Magnier S, Jondeau G. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 2007;99:406-409.
35. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwoger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873-2926.